After grabbing 15.0 million shares, the institutional investor is now in possession of 15.0 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 8.62% having worth around $64.2 million. Moreover, Paradigm BioCapital Advisors LP increased its share by 5.19 million to have a control over 14.41 million shares. And Tetragon Financial Management LP raised its holdings to 9.46 million shares by acquiring 9.46 million shares or 5.44% of the stake.
Autolus Therapeutics plc ADR (AUTL) concluded trading on 12/28/23 at a closing price of $6.63, with 2.72 million shares of worth about $18.01 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 190.79% during that period and on Thursday the price remained unchanged. Currently the company’s common shares owned by public are about 173.07M shares, out of which, 149.01M shares are available for trading.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 9 analysts are covering the AUTL stock and their offered price forecasts bring an average price target of $9.31. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $12.00 and could fall to a lowest price of $4.80. The stock’s current price level is 28.79% above of average price target set by the analysts, while a rise to estimated low would result in loss of -38.12% for the stock. However, touching the estimated high of $12.00 would mean a gain of 44.75% for the stock.
iShares Biotechnology ETF, Crown Sigma UCITS Plc – LGT Crown, and Regnan UFI – Regnan Global Equity are the top 3 mutual funds which are holding stakes in Autolus Therapeutics plc ADR iShares Biotechnology ETF is currently holding 0.72 million shares of worth totaling $3.07 million. The company recently came selling 4002.0 shares which brought its stake up to 0.41% of the company’s outstanding shares. Regnan UFI – Regnan Global Equity, after selling 0.41 million shares, have now control over 0.24% of the stake in the company. It holds 98183.0 shares of worth $1.77 million.
Autolus Therapeutics plc ADR (NASDAQ: AUTL) started trading at $6.61, below -$0.02 from concluding price of the previous day. Stock saw a price change of 20.55% in past 5 days and over the past one month there was a price change of 45.71%. Year-to-date (YTD), AUTL shares are showing a performance of 248.95% which increased to 276.70% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.61 but also hit the highest price of $6.94 during that period. The average intraday trading volume for Autolus Therapeutics plc ADR shares is 846.49K. The stock is currently trading 36.73% above its 20-day simple moving average (SMA20), while that difference is up 64.02% for SMA50 and it goes to 128.26% higher than SMA200.
Qatar Investment Authority acquired 15.0 million shares of Autolus Therapeutics plc ADR having value of about $64.2 million. Autolus Therapeutics plc ADR (NASDAQ: AUTL) currently have 173.07M outstanding shares and institutions hold larger chunk of about 63.44% of that. Holding of mutual funds in the company is about 1.59% while other institutional holders and individual stake holders have control over 61.85% and — of the stake respectively.
The stock has a current market capitalization of $1.15B and its 3Y-monthly beta is at 1.80. It has posted earnings per share of -$0.98 in the same period. It has Quick Ratio of 8.16 while making debt-to-equity ratio of 0.29. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for AUTL, volatility over the week remained 7.97% while standing at 8.68% over the month.
Analysts are in expectations that Autolus Therapeutics plc ADR (AUTL) stock would likely to be making an EPS of -$0.25 in the current quarter, while forecast for next quarter EPS is -$0.23 and it is -$0.87 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.29 which is -$0.2 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.23 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 36.76% while it is estimated to increase by 12.52% in next year.
Analysts at 9 brokerage firms have issued recommendations for the Autolus Therapeutics plc ADR (AUTL)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.44. Out of those 9 Wall Street analysts, 7 recommended a “Buy” rating, while 2 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Deutsche Bank on November 09, 2023 offering a Buy rating for the stock and assigned a target price of $10 to it.
